65,437 trials
Celiac Disease
Primary: Percentage of α1- and α2-gliadin-reactive CD4+ T Cells in Peripheral Blood Before Gluten Challenge — 0.00364; 0.00016; 0.00049; 0.00005 Percentage of T cells
Alzheimer Disease
Primary: Brain Penetrance of Dasatinib (D) — 0.27 ng/ml
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Mean Change in Intra-ocular Pressure — -4.25; -3.80; -4.22; -4.00 mmHG
Venous Thromboembolism (VTE) · Pulmonary Embolism · Deep Vein Thrombosis (DVT)
Primary: Number of Participants With Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated…
Solid Tumors
Primary: Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths — 4; 6; 4; 6 Participants
Tobacco Use Disorder
Primary: Number of Participants Willing to Complete 5 Days of tDCS or Sham — 7; 8 Participants
Asthma
Primary: Number of Unscheduled Healthcare Visits (UHCV) — 0.5; 0.5 number of visits — p=0.05
Pulmonary Arterial Hypertension
Primary: Change in Pulmonary Vascular Resistance (PVR) — 73.1; 46.6 dyn.sec/cm5
CHRONIC OBSTRUCTIVE PULMONARY DISEASE · ASTHMA · HEALTHY SUBJECTS
Primary: ANALYSIS OF LUNG DEPOSITION - Penetration Index — 0.8; 0.72; 0.69; 0.58 ratio
Knee Osteoarthritis
Primary: Change in Knee Adduction Moment Relative to Baseline — -0.21; -0.09; -0.21; -0.24 percentage of bodyweight x height
Chronic Low Back Pain
Primary: Change in Pain Assessed by Visual Analogue Scale (VAS) — -0.03; -0.10; -0.21 percentage of change in pain
Dermatomyositis, Adult Type
Primary: The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3…
Type 2 Diabetes
Primary: Change From Baseline in Percentage of Time With Continuous Glucose Monitoring (CGM) Sensor Glucose Values Between 70-180 Milligrams/Deciliter (mg/dL) (3.9-10.0…
Attention Deficit Disorder · Attention Deficit Disorder With Hyperactivity
Primary: Number of Extended Glances Away From Roadway During Driving Simulation — 16.5; 28.0 number of long glances — p=<.0001
Cytomegalovirus (CMV)
Primary: Number of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribose Nucleic Acid (DNA) at the End of Study Week 8 — 212; 190 Participants